A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Clinical trial NCT04878211 · TERMINATED
Trial details
- NCT number
- NCT04878211
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-10
- Primary completion
- 2023-04-14
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.